RUNX1 and prostate adenocarcinoma: The results suggested that the promoter region of RUNX1 exhibited hypomethylation in a variety of tumors, including BLCA, BRCA, COAD, GBM, HNSC, KIRC, LIHC, LUAD, lung squamous cell carcinoma (LUSC), PAAD, pheochromocytoma and paraganglioma (PCPG), READ, testicular germ cell tumors (TGCT), THCA, and UCEC, but hypermethylation in PRAD (Fig. 3A-P; all P < 0.05).